Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

RXi to spin off RNAi and focus on targeted cancer therapies

This article was originally published in Scrip

Executive Summary

RXi Pharmaceuticals, the Worcester, Massachusetts-based developer of targeted biotherapeutics, is to spin off its RNA interference therapy programmes to a new company and focus solely on its targeted cancer therapies. Both companies will be publicly traded, with the new RNAi business retaining the RXi name and the oncology-focused firm becoming Galena Biopharma. Concurrently, the firms will receive $12 million in financing from investors.

You may also be interested in...



RXi Thinks Self-Delivering RNAi Could Be The Ticket In A Tricky Field

Biotech's asymmetrical, shorter RNAi therapeutics are water-soluble and therefore can be self-delivering. Lead candidate RXI-109 is being studied in both hypertrophic and retinal scarring, but the firm has new funding that could help it move into oncology.

How Humira Finally Lost The Top Spot In Drug Sales

AbbVie’s Humira has been the world’s best-selling drug since 2012, and if it hadn’t been for COVID-19 it would most likely have been on track to retain its position for the 10th year in row.

Q3 Review: Editor’s Picks Of Scrip's Top Stories

From the latest COVID-19 advances to the emergence of a game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.

Topics

Related Companies

UsernamePublicRestriction

Register

SC014597

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel